

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:08:58 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Please take a look at this and respond if appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Idonae Lovetrue (b) (6) >
Sent: Friday, May 1, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Beigel, John (NIH) [E] (b) (6); Booth, Mason (NIH/NIAID) [C]
(b) (6) Kim, Sonnie (NIH/NIAID) [E] (b) (6)
Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Dear Dr. Fauci,

I'd like to share with you that the recent clinical trial results on remdesivir have validated our prediction of the remdesivir-specific post-treatment viral rebound in human COVID-19 patients. More details can be found in our official announcement <https://bit.ly/RRemdesivir>.

This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 (b) (4)

(b) (4)

(b) (4)